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Background: Unreconstructable critical ischemia with gangrene of the upper extremity is rarely due to atherosclerosis
alone, and few treatment options exist. We describe a patient with gangrene of both hands as a result of unreconstructable
atherosclerotic disease of both upper extremities who was successfully treated with tissue repair cells (TRCs) produced
from the patient’s bone marrow.
Methods: A patient with type 1 diabetes was referred with bilateral upper extremity digital gangrene due to unreconstruc-
table forearm and hand atherosclerosis. He was evaluated for therapeutic angiogenesis using TRCs.
Results: Following the intramuscular injection of TRCs produced from autologous bone marrow stem cells, the patient
demonstrated improved arterial perfusion and a durable clinical response with healing of all amputation sites and
cessation of pain.
Conclusions: The production of TRCs results in the expansion of stem and early progenitor cells, including CD90
mesenchymal cells and endothelial progenitor cells. This is the first reported case of end-stage upper extremity ischemia
treated with TRCs harvested from adult bone marrow. (J Vasc Surg 2010;52:723-9.)Unreconstructable critical limb ischemia (CLI) due to
atherosclerosis primarily occurs in the lower limbs and
results in amputation in up to 40% at one year.1 Unrecon-
structable critical ischemia with gangrene of the upper
extremity is infrequently due to atherosclerosis alone, with
most resulting from thromboangiitis obliterans or systemic
sclerosis. While no adequate approved alternative therapies
exist, angiogenesis using bone marrow stem cells has been
reported to improve outcomes in patients with upper ex-
tremity CLI.2 These patients had ischemic rest pain or
finger ulceration as a result of thromboangiitis obliterans
(Buerger’s disease) or collagen vascular disease as opposed
to atherosclerotic disease.
There is a growing body of literature documenting
clinical benefits of cell-based therapy for advanced coronary
artery disease3-5 and lower extremity arterial occlusive dis-
ease. These studies generally harvest large volumes of bone
marrow to obtain the necessary stem cells. We report the
first case of unreconstructable atherosclerotic disease of
both upper extremities treated successfully with tissue re-
pair cells (TRCs) produced from autologous adult bone
marrow stem cells.
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A 63-year-old man with a 46-year history of Type I diabetes
was referred with bilateral upper extremity digital gangrene (Fig
1). Fingertip ischemic rest pain and ischemic ulceration had begun
2 years earlier and progressed, resulting in increasing use of oral
narcotic analgesics and nonhealing amputations of the distal pha-
lanx of both index fingers and the left ring finger. Gangrene
progressed proximal to the amputation sites, and ischemic rest pain
developed in the right ring finger. A collagen vascular evaluation
was negative, and computed tomographic arteriography (CTA)
revealed unreconstructable forearm and hand atherosclerosis,
showing occlusion of all forearm arteries at the wrist and occlusion
of metacarpal and digital arteries. The patient was referred for
evaluation for therapeutic angiogenesis.
The patient’s history included hypertension, coronary artery
disease, atrial fibrillation, congestive heart failure, renal dysfunc-
tion, and lower extremity peripheral arterial disease (PAD).He had
undergone right below-knee amputation and a left femoral-to-
submalleolar posterior tibial artery bypass with saphenous vein
followed by amputation of two left toes. He denied tobacco use
and rarely used alcohol. Family history was noncontributory.
Axillary and brachial pulses were palpable bilaterally, but radial
and ulnar pulses were bilaterally absent. Themajority of the left index
finger was gangrenous, extending to the tip from 1.5 cm distal to the
web space. The right index finger had gangrene extending from the
proximal interphalangeal joint distally. The right ring finger showed
gangrene distal to the interphalangeal joint.
Lower extremities had palpable femoral pulses but no palpable
popliteal pulses. The patient had a well-healed right below-knee
amputation. The left femoral-to-posterior tibial artery bypass graft
was patent. The left foot was well perfused.
Upper extremity noninvasive studies demonstrated equal bra-
chial artery pressures and normal upper arm pulse volume record-
ings (PVRs). Forearm PVRs were attenuated, and the digital PVRs
were nearly flat (Fig 2). Radial and ulnar artery Doppler signals
were monophasic bilaterally. Bilateral arteriography demonstrated
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arteries of forearms and hands showed atherosclerotic occlusion
with severe small vessel disease of both hands (Fig 4) without
option for revascularization.
The Short Form (36)Health Survey (SF-36) was administered
to gauge quality-of-life (QOL), and his summary of physical func-
tioning was ranked 34/100. The patient scored “7” on a horizontal
Visual Analogue Scale (VAS) for bilateral upper extremity pain.
The patient was considered for treatment with TRCs prepared by
Fig 1. Photograph of hands at presentation. Patient und
ring finger.
Fig 2. Photoplethysmographic waveforms of fingers of
month, (C) 3 months, and (D) 12 months after treatmeAastrom Biosciences, Inc. (Ann Arbor, MI).A compassionate single-use protocol and Investigational New
Drug (IND) applicationwas approved by theUnited States Food and
Drug Administration and the ProMedica Health System institutional
review board. The patient had outpatient bonemarrow aspiration (47
cc) from the posterior iliac crest under local anesthesia. The bone
marrow was shipped to a centralized Aastrom Biosciences, Inc. pro-
cessing facility. Cell concentration was 41 106 /mL, viability 94%,
for a total of 1813 106 viable nucleated cells.
Using standard protocol, red blood cells and mature granulo-
nt prior amputation of right and left index fingers and left
and at (A) initial presentation (motion artifact), (B) 1
ight hand waveforms are similar.erweleft hcytes were removed using a Ficoll density gradient, resulting in 433 
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 106 viable mononuclear cells were inoculated into a closed
automated cell production system for clinical-scale ex vivo culture
of bone marrow derived stem and progenitor cells. The specifics of
the cell culture process have been previously described.6,7 After 12
days of culture, a total of 125  106 viable mononuclear cells
(TRCs) were harvested and washed in electrolyte solution. The
composition of TRCs is summarized in the Table. The CD90
mesenchymal cell population was 49-fold increased relative to the
number in the original mononuclear cell preparation. The CD90
cell subpopulation in the TRC product has been shown to contain
stem and progenitor cells and is therefore a useful surrogate marker
in this respect. Importantly, TRCs have been shown to contain
endothelial progenitor cells in colony formation assays and have
also been shown to possess endothelial tube-formation capacity in
vivo.8 The TRC culture process reduced the number of granulo-
cytes, T and B lymphocytes, and red blood cells by more than 70%.
Subsequent to expansion at the processing facility, the TRC
product was shipped back to the treatment center in a final product
volume of 5.5 mL. This volume was expanded to 9.5 mL at the
treatment center with the addition of sterile saline.
TRCs were injected via 15 intramuscular injections (0.3 mL
each) into the patient’s forearms ( 2 injections), web spaces, and
finger pads of both upper extremities during one treatment session
(Fig 5). Injection sites were chosen to deliver the majority of the
cells into ischemic tissues of the hand, as prespecified in the
protocol for the single-use IND.
Two months post-injection, the patient reported diminished
pain in his fingers and reduced need for analgesics. At 3 months, he
developed erythema, swelling, and purulent drainage from his left
and right index fingers as a result of demarcation and separation of
the gangrenous tissue and infection with methicillin-resistant
Fig 3. Digital subtraction arteriogram of both upper extremities
demonstrated that all arteries to and including the brachial arteries
were normal.staphylococcus aureus. Intravenous vancomycin was begun, andhe underwent amputation of the gangrenous tissue and infected
bone in both index fingers. These wounds were left open. The
distal phalanx of the left ring finger was amputated and closed with
a palmar flap. The distal phalanx of the right ring finger was
debrided. Good bleeding was observed in all wounds. He re-
mained on vancomycin and piperacillin/tazobactam and received
14 hyperbaric oxygen treatments to assist with infection control
during the week prior to discharge. His hands and proximal fingers
were pink and warm. Pulsatile perfusion as assessed by PVR was
markedly improved (Fig 2). All open amputation sites healed by
secondary intention, and the left ring finger flap healed primarily.
Six months postinjection, analgesics were no longer required
and the patient scored his worst pain as a “1” on a VAS. Laser
Doppler imaging was available and performed for both hands. Fig
5 shows uniform increased perfusion at specific injection sites.
Nine months following treatment, he reported no pain. All ampu-
tation sites were healed.
At his 12-month follow up (Fig 6), the patient rated “0” for
pain on a VAS and was no longer taking analgesics. The SF-36
results documented marked improvement in QOL, with a 35%
increase in his physical summary. Specifically, his physical function-
ing score increased by 15%, physical role functioning by 100%,
bodily pain by 29%, general health by 21%, and vitality by 20%.
DISCUSSION
Injection of TRCs into the ischemic tissue of a patient
with end-stage upper extremity ischemia due to multilevel
medium- and small-vessel atherosclerotic disease resulted
in increased arterial perfusion, elimination of ischemic rest
pain, and healing of all previously gangrenous digital am-
putation sites. Tissue perfusion was clinically improved, and
standardized photoplethysmography demonstrated mea-
surable increase. The patient’s clinical improvement and
objectively measured increased arterial perfusion persisted
beyond 1 year of follow up. The onset of improved perfu-
sion was evident at 1 month. Ischemic rest pain was dimin-
ished at 1 month and resolved by 3 months as documented
on the horizontal VAS for pain, which has been shown to
be a sensitive and accurate representation of pain intensity.9
Patients with advanced ischemia and gangrene face infe-
rior outcomes with medical therapies and/or revasculariza-
tion compared with patients with less severe clinical presenta-
tions, such as rest pain or digital ulceration.10 Critical limb
ischemia patientswith overt gangrene are often excluded from
investigations of new therapies because of poor prognosis. In
the absence of revascularization, amputation at the level of
gangrenous or ischemic tissue, as performedprior to referral in
this case, is futile and can lead to acceleration of necrosis and
significant risk of infection.
The underlying pathophysiology of upper extremity
CLI is important in terms of prognosis and response to
therapy. Inflammatory occlusive diseases, such as throm-
boangiitis obliterans (TAO) and collagen vascular dis-
ease (CVD), are different pathologic entities than ath-
erosclerotic occlusive disease. TAO patients respond
particularly well to therapeutic angiogenesis11 and have a
more favorable response than patients with atherosclero-
sis. However, patients with TAO and CVD of the upper
repair
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care. McClafferty et al12 followed 44 patients with upper
extremity CLI due to TAO or CVD for an average of
15.2 years. Patients with TAO appeared to have im-
proved outcomes compared with those with CVD; how-
ever, even in CVD patients, tissue loss was modest. Often
these patients have normal arterial perfusion to the wrist
but have distal small-vessel disease. The patient reported
herein had occlusion of both radial and ulnar arteries in
addition to advanced palmar and digital occlusive dis-
ease. The multilevel nature of his occlusive disease elim-
inated all options for surgical or endovascular interven-
tion and caused his severe ischemia (gangrene) with its
Fig 4. Bilateral arteriography showing severe occlusiv
bilaterally and small vessel disease of both hands.
Table. Comparison of tissue repair cells
Cell population Cell types labeled
Total viable bone marrow
mononuclear cells All cells
Stem and progenitor cells
% CD90 Mesenchymal stem and progenitor
Leukocytes
% CD45 All leukocytes
CD14 Auto Activated macrophages
CD66b Granulocytes
CD3 T cells
CD19 B cells
Red blood cells
% Gly-A Red blood cells and erythroid prec
TRC, Tissue repair cell.
aFold increase refers to the multiplier effect of the preparation of the tissueattendant poor prognosis. The patient’s unremittingischemic rest pain was an indicator of the additional
proximal tissue at risk of necrosis.
Autologous bone marrow cells represent an attrac-
tive alternative to gene therapy for therapeutic angiogen-
esis in patients with CLI. Bone marrow contains a mixed
population of cells such as fibroblasts, osteoblasts, myo-
genic cells, and endothelial cells. These can differentiate
into various tissues.6 However, when injected into isch-
emic tissue, bone marrow mononuclear cells are unlikely
to result in ectopic tissue formation.7,8 Tateishi et al13
investigated bone marrow-implanted limbs with immu-
nohistochemical methods and showed an increase in
capillary numbers but no evidence of either bone forma-
ease of the distal radial ulnar and interosseus arteries
Cell count at harvest
(culture inoculated cells)
[ 106]
Cell count
(TRC product)
[ 106]
Fold
increasea
300 125 0.4
0.8 39 49
289 86 0.3
0.8 32 40
183 20 0.1
32 9.2 0.3
19 1.1 0.1
s 105 1.0 0.01
cells product.e discells
ursortion or fibrosis.
Perf
prov
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cells important in angiogenesis.14,15 The tissue production
process occurs over 12 days in an automated, closed good
manufacturing practice-compliant system and results in the
expansion of stem and early progenitor cells, including
CD90 mesenchymal cells and endothelial progenitor
cells. TRCs have been shown to have proangiogenic poten-
tial in vitro and in vivo. Red blood cells, granulocytes, and
T and B lymphocytes are reduced in number relative to the
starting material.16
Mesenchymal cells (MSCs) and bone marrow mono-
nuclear cells have been injected into ischemic limbs.
Bone marrow mononuclear cells and MSCs differentiate
into endothelial cells; however, only MSCs differentiate
Fig 5. Laser Doppler imaging of patient 6 months a
specifically thenar and hypothenar eminences and all we
pretreatment photograph of the patient’s hands. (Laser D
Taken with PeriScan PIM3 System Laser Doppler Blood
Fig 6. Photograph of hands at 1 year showing iminto vascular smooth muscle cells.17 MSCs secrete sig-nificantly higher amounts of proangiogenic cytokines,
such as vascular endothelial growth factor, basic fibro-
blast growth factor, and stromal cell-derived factor-1-
alpha and are likely to become apoptotic under hypoxic
conditions.
The mechanism of improved perfusion following bone
marrow stem cell injection can be attributed to vasculogen-
esis, which is a result of the endothelial progenitor cells
derived from the mononuclear cells undergoing lineage-
specific differentiation into new blood vessel growth.18-20
As similar attempts with single-factor approaches to angio-
genesis for PAD patients have not been successful, the
angiogenic functions of TRCs as well as their modulation of
local inflammatory processes underscore the attractive hy-
reatment. (A) Note “hot spots” at sites of injection,
ces. The specific injection sites are indicated in the (B)
ler image courtesy of Perimed AB, Stockholm. Sweden.
usion Imager.)
ed perfusion and healing of all amputation sites.fter t
b spa
opppothesis that a multimodal approach to the ischemic limb
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action could be successful in variable limb ischemia circum-
stances.
Bartsch et al21 used both intraarterial and intramuscular
delivery of bone marrow mononuclear cells when they
treated 13 patients with chronic PAD and intermittent
claudication. Prior to injection, they induced limb ischemia
with a thigh blood pressure cuff to produce a hyperemic
response to maximize homing of the intraarterially deliv-
ered stem cells. Walking distance, ankle-brachial index,
capillary venous oxygen saturation, and venous occlusion
plethysmographic evaluation of arterial perfusion were all
improved.
Cobellis et al22 documented that two intraarterial
infusions of bone marrow mononuclear cells into the
femoral artery were well tolerated, although its necessity
or efficacy was not demonstrated. Nevskaya et al23 re-
ported two patients with ischemic fingers with ulceration
due to systemic sclerosis. One was treated with periph-
eral blood mononuclear cells and the other with bone
marrow mononuclear cells. Both patients experienced
ulcer healing, improved skin blood flow, and improved
flow-mediated brachial artery reactivity. However, after
treatment, circulating endothelial precursors were only
found in the patient treated with bone marrow stem
cells. This observation may be relevant to the durability
of response to treatment; however, the authors failed to
report long-term outcome.
Our patient is the first to be treated with bone
marrow harvested TRCs for gangrene of both hands
resulting from multilevel atherosclerotic disease and has
demonstrated improved arterial perfusion and durable
clinical response with healing and cessation of pain. The
TRC method is designed to create a mixed population of
cells with greatest potential efficacy for treating limb
ischemia while minimizing the discomfort and risk asso-
ciated with marrow harvest. Harvesting 60 cc of bone
marrow is sufficient to produce TRCs and has substantial
advantage over the 500 to 600 cc bone marrow volume
required when bone marrow stem cells are used primar-
ily. Sustained improved perfusion suggests that therapy
with TRCs may be biologically different and more dura-
ble than gene therapy using viral or plasmid vectors to
deliver intracellular pro-angiogenic proteins.24
TRCs are currently under evaluation in a randomized,
controlled trial of patients with CLI of the lower extremi-
ties. This case demonstrates the potential of TRC therapy
for advanced CLI. The randomized controlled trial will
offer a more objective look at the value of TRCs in a
broader base of patients with CLI.
The authors acknowledge the thoughtful contributions
of Jonathon Gertler, MD, and Marilyn Gravett, MFA, in
the preparation of this manuscript.
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